Kenneth H. Lundstrom, Ph.D. earned his Ph.D. from the University of Helsinki, Finland on overexpression of viral membrane proteins in Bacillus subtilis. He conducted postdoctoral research at Cetus Corporation in California on antisense expression and PCR technologies. Dr. Lundstrom then returned to his native Finland where he was appointed a senior scientist at Orion Pharmaceuticals where he worked on cloning, expression, and structural studies of catechol-o-methyltransferases.

From 1992 through 1995, Dr. Lundstrom developed Semliki Forest virus vectors for overexpression of receptors (GPCRs) and ion channels at the Glaxo Institute of Molecular Biology, in Geneva, Switzerland. He worked as a principal biologist at the Glaxo Medicines Research Centre in Stevenage, United Kingdom in 1995 and 1996. Between 1996 and 2001, he researched receptor expression in the central nervous system for Hoffmann-La Roche in Basel, Switzerland.

Dr. Lundstrom was appointed the scientific coordinator of the MePNet Program in 2001 and became the chief scientific officer of BioXtal in Lausanne, Switzerland in 2002. He is also part of the senior management team (vice president, science and technology) of Regulon Inc., Mountain View, California, a biotech company involved in cancer therapy. Dr. Lundstrom has published more than 100 scientific papers and reviews in international journals, acts as an editor for books in the fields of GPCRs, structural genomics and gene therapy, and is a frequent speaker at international conferences.

Mark L. Chiu, Ph.D. earned a bachelor's in biophysics from the University of California at Berkeley. He then joined Microgenics Corporation as a synthetic organic chemist. He later obtained his Ph.D. in biochemistry from the University of Illinois at Urbana-Champaign, working on the overexpression and biophysical characterizations of heme proteins. He began his postdoctoral work in the field of nuclear magnetic resonance methodology at the Federal Institute of Technology at Zurich, Switzerland and later joined the Biocenter of the University of Basel, working on the mechanisms of bacterial multidrug resistance and the general application of lipidic cubic phases for membrane protein crystallization. After that, he worked in the Department of Chemistry at Seton Hall University, characterizing properties of bacterial membrane proteins. Dr. Chiu is presently working in the department of structural biology at Abbott Laboratories, Abbott Park, Illinois, developing tools for structure-based drug design.

0 0

Post a comment